Results 61 to 70 of about 91,755 (270)

Nivolumab-Induced Ulcerative Keratitis—A Case Report [PDF]

open access: yes, 2020
Purpose: To describe a case of nivolumab-induced ulcerative keratitis rapidly recovering on topical steroid treatment and to determine changes in cytokine levels in the tear fluid caused by nivolumab.
Nuijts, R.   +6 more
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Cost-effectiveness of nivolumab in advanced melanoma : a drug review

open access: yes, 2020
: Introduction: The immune checkpoint inhibitors, including nivolumab, and targeted agents have dramatically improved the outcome for patients with unresectable advanced melanoma.
Specenier, Pol, Pol Specenier
core   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

open access: yesJournal for ImmunoTherapy of Cancer
Background For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown.
Borys Hrinczenko   +14 more
doaj   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

open access: yes, 2023
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years.
Gogas, Helen   +7 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Nivolumab-induced interstitial lung disease in the patient with melanoma

open access: yes
This article presents the case of a drug-induced interstitial lung disease in response to nivolumab, which is a programmed death receptor 1 (PD1) blocking antibody.
Marcin Morawski   +5 more
core   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

open access: yesBMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen   +9 more
wiley   +1 more source

Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors

open access: yes, 2018
Nivolumab plus ipilimumab achieves higher response rates than previously reported for nivolumab alone.

core   +1 more source

Home - About - Disclaimer - Privacy